Apply for funding for early-stage research into medical countermeasures, including vaccines, therapeutics and diagnostics, for chemical, biological, radiological and nuclear (CBRN) threats.
Who can apply
You must be employed at a research organisation eligible for MRC funding.
Applicant categories are a starting point. The official call decides eligibility.
Timing
Closing date: 20 January 2027 4:00pm UK time
How to apply
Apply through the funder’s official page (link below); it states the procedure, documents and deadline.
From the call text
Who can apply
Not stated in the call text we hold — check the official page
Company stage
Apply for funding for early-stage research into medical countermeasures, including vaccines, therapeutics and diagnostics, for chemical, biological, radiological and nuclear (CBRN) threats.
Single applicant or consortium
Not stated in the call text we hold — check the official page
Where applicants must be based
Not stated in the call text we hold — check the official page
Where to apply
Not stated in the call text we hold — check the official page
Where these facts come from
Fact
Value
How we know
Taken from the source
Deadline
20 January 2027 “Closing date: 20 January 2027 4:00pm UK time”
read from the official page
15 Nov 2026
Amount per applicant
Unknown — not stated in the source we hold
unknown
—
Total budget
Unknown — not stated in the source we hold
unknown
—
Funding rate
UKRI usually pays 80% of full economic cost for research organisations
programme standard rule
15 Nov 2026
Who can apply
You must be employed at a research organisation eligible for MRC funding.
Submit information about your longitudinal population study (LPS) to help Medical Research Council (MRC) plan for future investments in LPS infrastructure.
Apply for funding to establish a UK Obesity Research Institute, undertaking world-leading research into the mechanistic biomedical drivers of obesity and develop targeted…
Apply for funding to establish a Centre of Excellence for Regulatory Science and Innovation (CERSI) to address strategic regulatory science priorities through sustained p…